Lynn Morris to Young Adult
This is a "connection" page, showing publications Lynn Morris has written about Young Adult.
Connection Strength
0,659
-
Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. mSphere. 2020 Jan 29; 5(1).
Score: 0,104
-
HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes. J Virol. 2018 09 01; 92(17).
Score: 0,094
-
Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire. J Immunol. 2015 May 01; 194(9):4371-8.
Score: 0,075
-
Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology. 2010 Jun 20; 402(1):187-96.
Score: 0,053
-
Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern. Sci Rep. 2025 Feb 14; 15(1):5549.
Score: 0,037
-
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med. 2021 03 18; 384(11):1003-1014.
Score: 0,028
-
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Med. 2020 05; 17(5):e1003117.
Score: 0,027
-
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Med. 2020 02; 17(2):e1003038.
Score: 0,026
-
Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019 09 18; 11(510).
Score: 0,025
-
Provincial and national prevalence estimates of transmitted HIV-1 drug resistance in South Africa measured using two WHO-recommended methods. Antivir Ther. 2019; 24(3):203-210.
Score: 0,024
-
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018 07; 5(7):e366-e378.
Score: 0,023
-
Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa. J Antimicrob Chemother. 2017 Nov 01; 72(11):3141-3148.
Score: 0,022
-
Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. PLoS One. 2016; 11(9):e0161753.
Score: 0,021
-
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Clin Vaccine Immunol. 2016 06; 23(6):496-506.
Score: 0,020
-
Rapid disease progression in HIV-1 subtype C-infected South African women. Clin Infect Dis. 2014 Nov 01; 59(9):1322-31.
Score: 0,018
-
Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial. J Infect Dis. 2014 Jun 15; 209(12):1916-20.
Score: 0,017
-
Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. Virology. 2012 Nov 25; 433(2):410-20.
Score: 0,016
-
Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011 Mar 09; 6(3):e17518.
Score: 0,014
-
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010 Sep 03; 329(5996):1168-74.
Score: 0,013